Replies to post #234296 on Cytodyn Inc (CYDY)

[docj]

Welcome aboard the CYDY Ihub message board!

[docj]

MGK_2
•
9h ago
"Montefiore’s Neuro Bet: Beyond oncology, the Einstein/Montefiore preclinicals (March 2024) and Cornell’s Alzheimer’s pilot (December 2024) hint at CCR5’s brain inflammation role. A neurodegeneration win’s a $50B market—CYDY’s dark pool."

"27:15 Nader: Yeah, and BTD that we will be filing, Dr. Nitya Ray did a fantastic job on that. There were some patients with brain metastases*. Dr. Ray, explain to us, for a breakthrough designation strategy, are* we going to file for brain metastases and perhaps later on, if we do get BTD on the original submissions, maybe we want to ask for Basket Trial data, but tell us about the Basket Trial please.

27:60 Nitya Ray: The BTD application that is submitted is 28 patients from 3 different trials. And out of the 28, 6 had brain metastases*. They are* all mTNBC patients*. So we have submitted all of the results,* including all of the patients with brain metastases*, now with the FDA and FDA is reviewing it and we are waiting for FDA to respond for BTD application and we expect to hear from them in about 2 weeks. 2-3 weeks. Our CTA application I believe was submitted on November 5. So by January 5, we should hear from FDA. and then we are going to discuss with FDA and* see that forward with brain metastases*. Now,* these are not the only patients with brain metastases because these are mTNBC patients. But, we have other patients in the Basket Trial and not mTNBC, with brain metastases. And so we are very excited about what is happening with these patients. And so we are going to discuss this with the FDA and we do plan, after we receive the response from the FDA on the BTD application that is submitted, we are going to plan for perhaps another BTD just focusing on the brain metastases."

[docj]

MGK_2
•
9h ago
"Hütter’s Legacy Reload (Germany): Gero Hütter’s Berlin Patient cure—CCR5-delta 32 king, SAB relic. His 2008 win powers LATCH—a murmur from him flips HIV upside down."

"In September 2020, CytoDyn had this press release: https://www.globenewswire.com/news-release/2020/09/01/2086694/0/en/Global-Health-Leaders-Join-CytoDyn-s-Scientific-Advisory-Board.html

In it, CytoDyn "announced the formation and initial members of its Scientific Advisory Board today including leading HIV, NASH, Oncology, and Rheumatological clinical experts and researchers.

CytoDyn's Scientific Advisory Board members include Dr. Gero Hütter, German hematologist, best known for the bone marrow transplant resulting in the cure of the first HIV patient; Dr. Hope S. Rugo, Professor, Department of Medicine (Hematology/Oncology) and Director of the Breast Oncology Clinical Trials Education Program at University of California San Francisco; Dr. Richard T. Maziarz, Professor, Medical Director of the Adult Blood and Marrow Stem Cell Transplant and Cellular Therapy Program Knight Cancer Institute at Oregon Health & Science University (OHSU); Dr. Jonah B. Sacha, Professor, VGTI-Vaccine and Gene Therapy Institute at OHSU; Dr. Mazen Noureddin, a hepatologist and Director, Cedars-Sinai Liver Transplant Program in Los Angeles; Dr. Norman B. Gaylis, nationally and internationally recognized specialist in rheumatology and autoimmune diseases; Dr. Eric D. Mininberg, Oncology Specialist, Piedmont Cancer Institute, a member of the MD Anderson Cancer Network; and Dr. Lishomwa Ndhlovu, Assistant Professor, Immunology, Department of Medicine, Division of Infectious Disease at Weill Cornell Medicine in New York.""

[docj]

MGK_2
•
9h ago
"Hope Rugo’s TNBC Nuke (UCSF): She ran leronlimab with carboplatin in 2019—stable disease at ASCO 2020. January 15 news says her 2025 TNBC basket trial’s live. Her bio whispers “CCR5 research”—leronlimab in there? It’s a sleeper atom bomb. Rugo’s a cancer titan; this could 3x CYDY in a flash."

"Dr. Hope Rugo is the Director of the Breast Oncology Clinical Trials Program at UCSF. She is the principal investigator for multiple clinical trials studying novel targeted therapeutics combined with standard treatments to improve clinical results in early and late-stage breast cancer*. She is also researching cognitive function in patients receiving chemotherapy for breast cancer* as well as ways to reduce toxicity from therapy .

from here: https://www.theoncologypharmacist.com/confere...ast-cancer

Quote:Dr. Hope Rugo attempts to dispel this misconception, citing that endocrine therapy and CDK4/6 inhibitors are well tolerated and don’t have the intensive side effects associated with chemotherapy ."

[Monroe1]

Welcome back Yahsho. As before your posts have been right on.

" confirmed that a small group of patients who failed treatment after developing metastatic disease survived more than 36 months after receiving leronlimab, are alive today, and currently identify as having no evidence of ongoing disease."

Dr. Jacob Lalezari, CEO of CytoDyn ( CYDY ), added: “These provocative observations of improved survival in patients with mTNBC and prior treatment failure in the metastatic setting, including reported clearance of disease in a group of long-term survivors, provides early clinical evidence of leronlimab’s potential impact in the treatment of TNBC and other solid tumors. I expect the Company’s oncology efforts to accelerate in the coming months, with further announcements in both mTNBC and colorectal cancer.”

Based on these survival observations, the Company has initiated two pre-clinical studies in mTNBC that will evaluate possible treatment synergies between leronlimab, an antibody-drug complex treatment (sacituzumab govitecan), and an immune checkpoint inhibitor (pembrolizumab). The Company will also continue to perform follow-up testing on the group of mTNBC survivors who currently identify as having no evidence of ongoing disease.


Already seems the demand is knocking down the doors at CytoDyn. As word gets out Dr. J may need a security robot!!! 2025 AND BEYOND sin duda.

[Yahsho]

Cooooooooked cooooked I tell you. Wait till more news drops don’t cover. Keep drowning.